Checchi Capital Advisers LLC Has $565,000 Stock Holdings in Medtronic PLC $MDT

Checchi Capital Advisers LLC trimmed its holdings in Medtronic PLC (NYSE:MDT) by 3.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,479 shares of the medical technology company’s stock after selling 252 shares during the period. Checchi Capital Advisers LLC’s holdings in Medtronic were worth $565,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of MDT. 1248 Management LLC bought a new stake in shares of Medtronic during the 1st quarter worth about $26,000. Columbia River Financial Group LLC acquired a new position in Medtronic during the first quarter valued at approximately $28,000. Twin Tree Management LP bought a new position in shares of Medtronic in the first quarter valued at approximately $29,000. Activest Wealth Management lifted its stake in shares of Medtronic by 3,577.8% in the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after buying an additional 322 shares during the last quarter. Finally, Hughes Financial Services LLC bought a new stake in shares of Medtronic during the 1st quarter worth $32,000. Institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wolfe Research raised shares of Medtronic from an “underperform” rating to a “peer perform” rating in a research report on Monday, June 30th. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research report on Friday. Argus raised their target price on Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, August 26th. Evercore ISI lifted their price target on Medtronic from $103.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Finally, UBS Group increased their price objective on Medtronic from $94.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.94.

Insider Activity

In related news, Director William R. Jellison bought 2,500 shares of the company’s stock in a transaction dated Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, with a total value of $230,925.00. Following the acquisition, the director owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.26% of the company’s stock.

Medtronic Price Performance

Shares of MDT stock opened at $98.46 on Tuesday. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $98.66. The company has a market capitalization of $126.29 billion, a P/E ratio of 27.12, a P/E/G ratio of 2.57 and a beta of 0.78. The stock has a 50 day moving average of $93.07 and a two-hundred day moving average of $88.52. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. During the same period in the prior year, the company posted $1.23 earnings per share. Medtronic’s revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, equities analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s payout ratio is presently 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.